South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
SAN FRANCISCO, Feb. 15, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in Stemline Therapeutics, Inc. (NASDAQ:STML) to the expanded class period in the pending securities class action and reminds them of the April 4, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of Stemline (1) pursuant to Stemline’s secondary public offering on or about January 20, 2017 or (2) on the open market between January 6, 2017 and February 1, 2017 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/STML
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On February 2, 2017, TheStreet published an article entitled “Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial, the Company Raises Money.” TheStreet reported that investors who bought into a $45 million Stemline Therapeutics stock offering on January 19, 2017 were not told that one day prior to the financing, a cancer patient in a clinical trial died from a severe side effect, a type of low blood pressure, tied to the Company’s SL-401 drug.
This news drove the price of Stemline shares down over 42% on February 2, 2017.
“A cancer patient’s death occurring from Stemline SL-401 related side effects is a tragic event and is a fact reasonable investors would want to know about,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Stemline should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
